Cabozantinib: tested in a combination
103 studies: another drug in the study is under test too. Page 1 of 2. Open to participants first (27), then studies with results posted, then the rest; newest registration first within each.
- Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored StudyEnrolling by invitationNCT07620574Phase 3Report a problem
- Extension Study for Participants in Studies That Include Belzutifan (MK-6482-043/LITESPARK-043)RecruitingNCT07405164Phase 3Report a problem
- Metastatic Ewing's Trial Testing Schedule Enhancement to Improve OutcomesRecruitingNCT07194044Phase 1Report a problem
- Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort StudyNot yet recruitingNCT07010393Phase 4Report a problem
- Cabozantinib and Nivolumab Among Older Patients With Renal Cell CarcinomaRecruitingNCT06934057Phase 4Report a problem
- A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingNCT06835972Phase 1/2Report a problem
- Study of Cabozantinib With Selumetinib for Plexiform NeurofibromasRecruitingNCT06502171Phase 1Report a problem
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingNCT06482086Phase 2Report a problem
- CARE1 Pragmatic Clinical TrialRecruitingNCT06364631Phase 3Report a problem
- Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical CancerRecruitingNCT06006013Phase 2Report a problem
- A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)Not yet recruitingNCT05859217Phase 2Report a problem
- A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)RecruitingNCT05613413Phase 2Report a problem
- Cabozantinib and Dostarlimab in Recurrent Gynecologic CarcinosarcomaRecruitingNCT05559879Phase 1/2Report a problem
- Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC StudyRecruitingNCT05361720Phase 2Report a problem
- Combination of Pembrolizumab and Cabozantinib in Patients With Advanced SarcomasRecruitingNCT05182164Phase 2Report a problem
- BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot StudyRecruitingNCT05136196Phase 2Report a problem
- Cabozantinib and Lanreotide as Treatment for Gastroenteropancreatic Neuroendocrine TumorsRecruitingNCT05048901Phase 1/2Report a problem
- A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain MetastasesRecruitingNCT05048212Phase 2Report a problem
- Atezolizumab and Cabozantinib for the Treatment of Adolescents and Young Adults With Recurrent or Metastatic Osteosarcoma, TACOS StudyRecruitingNCT05019703Phase 2Report a problem
- A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)RecruitingNCT04893785Phase 2Report a problem
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingNCT04472767Phase 2Report a problem
- A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.RecruitingNCT04116541Phase 2Report a problem
- Immune Checkpoint Therapy vs Target Therapy in Reducing Serum HBsAg Levels in Patients With HBsAg+ Advanced Stage HCCRecruitingNCT03899428Phase 2Report a problem
- Pan Tumor Rollover StudyRecruitingNCT03899155Phase 2Report a problem
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingNCT03866382Phase 2Report a problem
- Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal MalignanciesRecruitingNCT03539822Phase 1/2Report a problem
- The Drug Rediscovery Protocol (DRUP Trial)RecruitingNCT02925234Phase 2Report a problem
- Study of Ipilimumab, Nivolumab, and Cabozantinib in Patients With Cutaneous MelanomaTerminatedNCT05200143Phase 2Results postedReport a problem
- Cabozantinib and Pembrolizumab in Metastatic PancreasCompletedNCT05052723Phase 2Results postedReport a problem
- Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic CancerCompletedNCT04820179Phase 2Results postedReport a problem
- Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIVActive, not recruitingNCT04514484Phase 1Results postedReport a problem
- Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing ChemotherapyCompletedNCT04471428Phase 3Results postedReport a problem
- Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCActive, not recruitingNCT04446117Phase 3Results postedReport a problem
- Cabozantinib and Pembrolizumab for the First-Line Treatment of Advanced Liver CancerTerminatedNCT04442581Phase 2Results postedReport a problem
- Trial of Cabozantinib Plus Atezolizumab in Advanced and Progressive Neoplasms of the Endocrine System. The CABATEN StudyCompletedNCT04400474Phase 2Results postedReport a problem
- Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue SarcomaActive, not recruitingNCT04339738Phase 2Results postedReport a problem
- Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue SarcomaActive, not recruitingNCT04200443Phase 2Results postedReport a problem
- Cabozantinib and Nivolumab for Carcinoid TumorsCompletedNCT04197310Phase 2Results postedReport a problem
- Ph II Study of Cabozantinib With Pembrolizumab in Metastatic Gastric and Gastroesophageal AdenocarcinomaCompletedNCT04164979Phase 2Results postedReport a problem
- Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced MelanomaActive, not recruitingNCT04091750Phase 2Results postedReport a problem
- Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsActive, not recruitingNCT04079712Phase 2Results postedReport a problem
- Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid CancerActive, not recruitingNCT03914300Phase 2Results postedReport a problem
- Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer TherapyActive, not recruitingNCT03755791Phase 3Results postedReport a problem
- Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid CancerTerminatedNCT03630120Phase 2Results postedReport a problem
- Cabozantinib Plus Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Advanced Urothelial CarcinomaCompletedNCT03534804Phase 2Results postedReport a problem
- Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung CancerCompletedNCT03468985Phase 2Results postedReport a problem
- Pembrolizumab & Cabozantinib in Patients With Head and Neck Squamous Cell CancerActive, not recruitingNCT03468218Phase 2Results postedReport a problem
- Cabozantinib S-malate and Nivolumab in Treating Patients With Advanced, Recurrent, or Metastatic Endometrial CancerActive, not recruitingNCT03367741Phase 2Results postedReport a problem
- A Phase II Study of Nivolumab in Combination With Cabozantinib for Metastatic Triple-negative Breast CancerCompletedNCT03316586Phase 2Results postedReport a problem
- Cabozantinib and Erlotinib for Patients With EGFR and c-Met Co-expressing Metastatic Pancreatic AdenocarcinomaTerminatedNCT03213626Phase 2Results postedReport a problem
- A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell CarcinomaCompletedNCT03141177Phase 3Results postedReport a problem
- Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsCompletedNCT02795156Phase 2Results postedReport a problem
- Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has ProgressedCompletedNCT02761057Phase 2Results postedReport a problem
- Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung CancerCompletedNCT01866410Phase 2Results postedReport a problem
- Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney CancerCompletedNCT01835158Phase 2Results postedReport a problem
- Cabozantinib-S-Malate Compared With Temozolomide or Dacarbazine in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed by SurgeryCompletedNCT01835145Phase 2Results postedReport a problem
- Cabozantinib or Paclitaxel in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cavity CancerCompletedNCT01716715Phase 2Results postedReport a problem
- Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung CancerActive, not recruitingNCT01708954Phase 2Results postedReport a problem
- An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedNCT01658878Phase 1/2Results postedReport a problem
- Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate CancerCompletedNCT01630590Phase 2Results postedReport a problem
- A Study of Cabozantinib and Nivolumab With Radiation Therapy for People With Renal Cell Carcinoma That Has Spread to the BrainActive, not recruitingNCT06132945Phase 1Report a problem
- Study of Cabozantinib and Nivolumab in Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT05502315Phase 2Report a problem
- Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular CarcinomaWithdrawnNCT05327738Phase 2Report a problem
- Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)CompletedNCT05289856Phase 2Report a problem
- Study of Cabozantinib With Lu-177 in Patients With Somatostatin Receptor 2 Positive Neuroendocrine TumorsActive, not recruitingNCT05249114Phase 1Report a problem
- Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1Report a problem
- Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT05168618Phase 2Report a problem
- Biomarker-driven Therapy for MelanomaCompletedNCT05063058Not applicableReport a problem
- A Phase II Study to Evaluate the Effects of Sequential Therapy With the Anti c-MET/VEGFR Tyrosine Kinase Inhibitor (TKI), Cabozantinib, Followed by an Anti-PD-1 Antibody (Nivolumab) in Patients With Advanced HCC Who Progressed on First-line TherapyWithdrawnNCT05039736Phase 2Report a problem
- Atezolizumab and Cabozantinib for the Treatment of Recurrent GlioblastomaActive, not recruitingNCT05039281Phase 1/2Report a problem
- Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT05007613Phase 2Report a problem
- Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal CancerActive, not recruitingNCT04963283Phase 2Report a problem
- Study of Cabozantinib Plus TAS102 in mCRC as Salvage TherapyCompletedNCT04868773Phase 1Report a problem
- Cabozantinib With Topotecan-CyclophosphamideCompletedNCT04661852Phase 1Report a problem
- Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell CarcinomaStatus unknownNCT04644432Phase 2Report a problem
- Cabozantinib Combined With PD-1 and CTLA-4 Inhibition in Metastatic Soft Tissue SarcomaActive, not recruitingNCT04551430Phase 2Report a problem
- Cabozantinib and Abiraterone With Checkpoint Inhibitor Immunotherapy in Metastatic Hormone Sensitive Prostate Cancer (CABIOS Trial)CompletedNCT04477512Phase 1Report a problem
- A Trial Aiming to Assess the Safety and Activity of the Combination of Cabozantinib Plus Lanreotide in GEP and NETStatus unknownNCT04427787Phase 2Report a problem
- Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCActive, not recruitingNCT04413123Phase 2Report a problem
- CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase InhibitionActive, not recruitingNCT04322955Phase 2Report a problem
- Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung CancerActive, not recruitingNCT04310007Phase 2Report a problem
- Study of CAbozantinib in Combination with AtezolizumaB for Muscle-Invasive BladdEr CancerActive, not recruitingNCT04289779Phase 2Report a problem
- Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical CancerTerminatedNCT04230954Phase 2Report a problem
- Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant MesotheliomaTerminatedNCT04173338Phase 1Report a problem
- A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and ChemotherapyWithdrawnNCT04151563Phase 1/2Report a problem
- Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic CarcinosarcomaWithdrawnNCT04149275Phase 2Report a problem
- hARnessing CAbozantinib and Durvalumab Immuno-oncology Association: ARCADIA Study"Status unknownNCT03824691Phase 2Report a problem
- A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab StudyActive, not recruitingNCT03768063Phase 3Report a problem
- Cabozantinib in Combination With Cetuximab in Patients With Recurrent or Metastatic Head and Neck Squamous Cell CancerCompletedNCT03667482Phase 1Report a problem
- A Study of Nivolumab In Combination With Cabozantinib in Patients With Non-Clear Cell Renal Cell CarcinomaActive, not recruitingNCT03635892Phase 2Report a problem
- Cabozantinib in Advanced Adrenocortical CarcinomaActive, not recruitingNCT03612232Phase 2Report a problem
- Cabozantinib in Combination With 13-cis-Retinoic Acid in Children With Relapsed or Refractory Solid TumorsCompletedNCT03611595Phase 1Report a problem
- Cabozantinib or Sunitinib Malate in Treating Participants With Metastatic Variant Histology Renal Cell CarcinomaActive, not recruitingNCT03541902Phase 2Report a problem
- Niraparib in Combination with Cabozantinib (XL184) in Patients with Advanced Urothelial Cancer (NICARAGUA)CompletedNCT03425201Phase 1/2Report a problem
- Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)CompletedNCT03299946Phase 1Report a problem
- Efficacy and Safety of Precision Therapy in Refractory TumorStatus unknownNCT03239015Phase 2Report a problem
- Cabometyx and Avelumab in Patients With Metastatic Renal Cell Carcinoma (mRCC)CompletedNCT03200587Phase 1Report a problem
- Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsActive, not recruitingNCT03170960Phase 1Report a problem
- Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients With Metastatic Endocrine CancerCompletedNCT02592356Not applicableReport a problem
- Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary TumorsActive, not recruitingNCT02496208Phase 1Report a problem